US20140370101A1 - 2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor - Google Patents

2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor Download PDF

Info

Publication number
US20140370101A1
US20140370101A1 US14/374,220 US201214374220A US2014370101A1 US 20140370101 A1 US20140370101 A1 US 20140370101A1 US 201214374220 A US201214374220 A US 201214374220A US 2014370101 A1 US2014370101 A1 US 2014370101A1
Authority
US
United States
Prior art keywords
biphenol
injection
grade
homogenous
lipid microsphere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/374,220
Other languages
English (en)
Inventor
Rutao Wang
Tao Chen
Shupan Guo
Huijing Hu
Long An
Weijiao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XI'AN LIBANG PHARMACEUTICAL CO Ltd
Original Assignee
XI'AN LIBANG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XI'AN LIBANG PHARMACEUTICAL CO Ltd filed Critical XI'AN LIBANG PHARMACEUTICAL CO Ltd
Assigned to XI'AN LIBANG PHARMACEUTICAL CO., LTD reassignment XI'AN LIBANG PHARMACEUTICAL CO., LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AN, Long, CHEN, TAO, GUO, Shupan, HU, Huijing, WANG, RUTAO, WANG, WEIJIAO
Publication of US20140370101A1 publication Critical patent/US20140370101A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Definitions

  • This invention relates to 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and the preparation methods therefor, in the field of pharmaceutical preparations.
  • biphenol 2,2′,6,6′-tetraisopropyl-4,4′-biphenol
  • biphenol is an anti-epileptic compound newly developed (Chinese patent CN 101804043A, Uses of biphenol and its derivatives in drugs for the treatment of epilepsy) for treating many epileptic symptoms such as generalized tonic-clonic seizures (grand mal), absence seizures (petit mal), simple partial seizures, complex partial seizures (psychomotor seizures), autonomic seizures (periodic seizures) and others.
  • Experimental studies have shown that biphenol has a strong affinity towards GABA receptors and is a GABA agonist, while it is an antagonist for NMDA receptors for regulating the Ca 2+ influx in Ca 2+ channels.
  • the present invention provides a 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparation and its preparation method.
  • 0.5 ⁇ 1% of antioxidants were added to the preparation to address the issue that biphenol is easily oxidizable.
  • vitamin E a potent, lipid soluble antioxidant, is used for ensuring the stability of the drug in the preparation.
  • This invention uses only phospholipid emulsifiers in an amount of 1 to 1.5% without any co-solvent so as to prevent hemolysis and production of substances that may otherwise cause thrombotic inflammation.
  • the emulsifiers of this invention are egg lecithin derived from the yolk of animal embryos which are easier and safer to be absorbed by the human body.
  • the lipid microsphere preparations of this invention are prepared by the processing of active ingredients comprising 2,2′,6,6′-tetraisopropyl-4,4′-biphenol (hereinafter referred as biphenol), injection-grade oil, emulsifier, and injection-grade water.
  • active ingredients comprising 2,2′,6,6′-tetraisopropyl-4,4′-biphenol (hereinafter referred as biphenol), injection-grade oil, emulsifier, and injection-grade water.
  • biphenol 2,2′,6,6′-tetraisopropyl-4,4′-biphenol
  • injection-grade oil injection-grade oil
  • emulsifier injection-grade water
  • injection-grade water injection-grade water.
  • All units are in percentage by weight.
  • the injection-grade oil is selected from one or more of soybean oil, medium chain triglyceride oil, sea buckthorn oil, and tea oil.
  • the emulsifier is selected from one or more of soy lecithin, hydrogenated lecithin, synthetic lecithin, and egg lecithin.
  • the antioxidant is selected from one or more of vitamin E, ascorbic acid, and sodium hydrogen sulfite.
  • the lipid microsphere preparation of this invention has the following composition.
  • Every 100 ml of lipid microsphere preparation comprises 1000 mg of biphenol, 10 g of soybean oil, 1.2 g of injection-grade egg lecithin for injection, 1 g of vitamin E, 2.5 g of glycerin, 0.5 g EDTA, and the remaining being injection-grade water.
  • This invention also aims to provide a method for preparing biphenol lipid microsphere preparations.
  • the preparation method of this invention comprises the following steps:
  • said method for preparing biphenol lipid microsphere preparations comprises the following steps:
  • the preparation of this invention is a lipid microsphere preparation for use in intravenous injections.
  • the particle size of the lipid microspheres of this invention is in the range of 100 nm ⁇ 800 nm with the average particle size being 150 nm ⁇ 300 nm.
  • biphenol is encapsulated within lipid microspheres which greatly increase its solubility in water, the amount of drug that can be loaded, and also the stability of the preparation. Further, being a novel drug carrier, lipid microspheres are non-toxic, non-immunogenic, reducing irritation due to the drug and decreasing the drug's toxic side effects.
  • This invention increases the stability of the injection, extends the drug's shelf life, improves its solubility and ensures its safeness. Moreover, the simple and feasible preparation process of the present invention is time and cost effective such that it is well suited for mass production. Furthermore, the formula and preparation methods for the preparation of this invention have been scientifically screened and proven.
  • the preparation of this invention relates to anti-epileptic preparations.
  • the anti-epileptic preparation of this invention has significantly higher efficacy in comparison to CMCNa-biphenol.
  • the method for administering the drug is switched from oral administration to intravenous injection which improves drug absorption and increases the therapeutic effect of the drug;
  • the preliminary emulsion was homogenized with a high-pressure homogenizer and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • Drugs and Excipients Amount (g) Biphenol 10.0 Injection-grade Soybean oil 300 Soy lecithin 15 Vitamin E 10 Glycerin 25 EDTA 5 Injection-grade water make up to 1000 ml
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • Drugs and Excipients Amount (g) Biphenol 10.0 Injection-grade Soybean oil 100 Hydrogenated Lecithin 12 Vitamin E 10 Glycerin 25 EDTA 5 Injection-grade water make up to 1000 ml
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • Drugs and Excipients Amount (g) Biphenol 10.0 Injection-grade Soybean oil 100 Synthetic phospholipids 12 Vitamin E 10 Glycerin 25 EDTA 5 Injection-grade water make up to 1000 ml
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the preliminary emulsion was homogenized with a high-pressure homogenizer for 5 ⁇ 8 times at 800 ⁇ 900 bar and filtered with a microporous membrane filter before being flushed with nitrogen, sealed, autoclaved at 115° C. to obtain the final product.
  • the osmolarity of the final emulsion was determined to be 300 ⁇ 400 mOsm/L by an osmometer (freezing point depression method) which fulfilled the requirement for a lipid microsphere preparation to be used for intravenous injection.
  • the biphenol lipid microspheres prepared were kept at 4° C. for 6 months before subjected to 45° C. for 6 months and, after which, were placed at room temperature for 12 months.
  • the stability of the products was evaluated in terms of their appearance, pH and encapsulation efficiency. Results are shown in Table 1.
  • Example 0 mth Homogenous Homogenous Homogenous 7.85 7.86 7.84 98.45 98.35 98.46 1 1 mth Homogenous Homogenous Homogenous 7.74 7.71 7.68 98.45 98.38 98.45 2 mth Homogenous Homogenous Homogenous 7.66 7.64 7.55 98.40 98.36 98.44 3 mth Homogenous Homogenous Homogenous 7.54 7.66 7.46 98.41 98.37 98.45 6 mth Homogenous Homogenous Homogenous 7.32 7.52 7.29 98.38 98.25 98.36 9 mth — Homogenous — — 7.48 — — 98.26 — 12 mth — Homogenous — — 7.31 — — 98.23 — Example 0 mth Homogenous Homogenous Homogenous 7.94 7.84 7.91 98.54
  • the lipid microspheres of this invention have good stability. No significant change to their appearance and encapsulation efficiency was noticed after being placed at 4° C. for 6 months followed by 45° C. for 6 months and, subsequently, placed at room temperature for 12 months. Although there were some degrees of decrease in pH, this did not affect the stability of the preparations.
  • lipid microsphere preparations prepared according to this invention possessed good stability which met the requirements on the stability of preparations stipulated in China's National Guidelines on Novel Drug Research.
  • the biphenol content in this invention was determined by high performance liquid chromatography.
  • a C18 column (4.6 mm ⁇ 200 mm, 5 ⁇ m) was used with methanol-acetonitrile-water (60:22:18) as the mobile phase at a flow rate of 1.0 ml/min and UV detection at 275 nm.
  • Lipid microsphere preparations were centrifuged at 10000 r/min for 30 minutes by ultracentrifugation. 0.5 ml of the supernatant was obtained and dissolved with isopropyl alcohol and the biphenol content was characterized with high performance liquid chromatography to determine the encapsulated biphenol content, M1. The total biphenol content in lipid microsphere preparation is M0. The following formula was used for calculating the encapsulation efficiency which is the weight ratio of biphenol lipid microspheres to biphenol.
  • Three groups of 8 guinea pigs were randomly separated based on their weight. Each of the guinea pigs from group 1 and group 2 was given 3 successive peritoneal injections of the biphenol lipid microsphere preparations at a dose of 0.5 ml/guinea pig every other day to induce sensitization. On day 14 and day 21 after the first peritoneal injection, guinea pigs from groups 1 and 2 were given intravenous injections of the biphenol lipid microsphere preparations at the toe at a dose of 1.0 ml/guinea pig so as to cause stimulation.
  • the guinea pigs were given 3 successive peritoneal injections of 20% egg white at a dose of 0.5 ml/guinea pig every other day to induce sensitization and, after 14 days, were given intravenous injection of egg white at the toe at a dose of 1.0 ml/guinea pig so as to cause stimulation. All three groups were observed for 15 minutes after injection to notice for allergic reactions.
  • results The two groups of guinea pigs injected with biphenol lipid microspheres which received the stimulation dose of same drug on day 14 and day 21 respectively did not show any allergic response.
  • the guinea pigs in the positive control group had breathing difficulty and spasm within 2 minutes after injection before they died. The death of the guinea pigs were within 1 ⁇ 3 minutes after injection.
  • Biphenol lipid microsphere preparations were intravenously injected at the left ear of 2 New Zealand white rabbits at a dose of 5 ml/kg while 10% sucrose injections were intravenously injected at the right ear at a dose of 5 ml/kg.
  • the injections were given daily for a total of five days. The injection site was observed for any swelling or rashes since day 1. Within 24 hours after the last injection, the ears were removed and fixed in 10% formalin before being prepared for histopathological examination.
  • the allergy test, hemolytic test and irritation test on the lipid microsphere preparations of this invention showed that the lipid microsphere preparations of this invention are highly stable and do not cause any allergic, hemolytic or irritation effects. It therefore complies with the relevant requirements for clinically used drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
US14/374,220 2012-02-06 2012-03-07 2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor Abandoned US20140370101A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2012100256112 2012-02-06
CN2012100256112A CN102525921B (zh) 2012-02-06 2012-02-06 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
PCT/CN2012/072031 WO2013117022A1 (fr) 2012-02-06 2012-03-07 Préparation de microsphères lipidiques de 2,2',6,6'-tétraisopropyl-4,4'-2-biphénol et leur procédé de préparation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/072031 A-371-Of-International WO2013117022A1 (fr) 2012-02-06 2012-03-07 Préparation de microsphères lipidiques de 2,2',6,6'-tétraisopropyl-4,4'-2-biphénol et leur procédé de préparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/141,517 Continuation US10154967B2 (en) 2012-02-06 2016-04-28 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and preparation methods therefor

Publications (1)

Publication Number Publication Date
US20140370101A1 true US20140370101A1 (en) 2014-12-18

Family

ID=46334755

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/374,220 Abandoned US20140370101A1 (en) 2012-02-06 2012-03-07 2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor
US15/141,517 Active US10154967B2 (en) 2012-02-06 2016-04-28 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and preparation methods therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/141,517 Active US10154967B2 (en) 2012-02-06 2016-04-28 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and preparation methods therefor

Country Status (6)

Country Link
US (2) US20140370101A1 (fr)
EP (1) EP2813215B1 (fr)
JP (1) JP5748926B2 (fr)
CN (1) CN102525921B (fr)
CA (1) CA2865777C (fr)
WO (1) WO2013117022A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180185299A1 (en) * 2015-01-13 2018-07-05 Xi'an Libang Pharmaceutical Co., Ltd The use of diphenol in preparation of medicines for prevention and treatment of cerebral ischemia
US10154967B2 (en) 2012-02-06 2018-12-18 Xi'an Libang Pharmaceutical Co., Ltd 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and preparation methods therefor
US10329243B2 (en) * 2015-01-13 2019-06-25 Xi'an Libang Pharmaceutical Co., Ltd Biphenyl derivative and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112336868A (zh) * 2020-10-28 2021-02-09 西安力邦医美科技有限公司 聚乙基亚胺苦参碱脂微球抗真菌制剂及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714520A (en) * 1994-03-22 1998-02-03 Zeneca Limited Propofol compostion containing edetate
US20020025337A1 (en) * 1995-07-20 2002-02-28 Lisbeth Illum Lipid vehicle drug delivery composition containing vitamin e
US6572884B1 (en) * 1999-07-28 2003-06-03 Daftary Gautam Vinod Parenteral Cisplatin emulsion
US20040137049A1 (en) * 2001-03-01 2004-07-15 Pai Srikanth Annappa Amphotericin b aqueous composition
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20070026058A1 (en) * 2004-05-11 2007-02-01 Lena Pereswetoff-Morath Method and composition for treating rhinitis
CN101804043A (zh) * 2010-04-30 2010-08-18 西安力邦制药有限公司 二联苯酚及其衍生物在治疗癫痫药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
CN1478465A (zh) * 2003-07-14 2004-03-03 丽 佟 含油脂的联苯双酯液体药物组合物
JP2009503059A (ja) * 2005-08-05 2009-01-29 ブハラット セルムズ アンド ヴァクシンズ リミテッド 防腐効果を有する静脈プロポフォールエマルジョン組成物
WO2008023384A1 (fr) * 2006-08-24 2008-02-28 Bharat Serums & Vaccines Ltd. Compositions de propofol sous forme d'emulsion administrées par voie intraveineuse
CN101940549B (zh) * 2010-08-27 2012-04-25 北京中海康医药科技发展有限公司 一种氟比洛芬酯中长链脂肪乳及制备方法
CN102525921B (zh) 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714520A (en) * 1994-03-22 1998-02-03 Zeneca Limited Propofol compostion containing edetate
US20020025337A1 (en) * 1995-07-20 2002-02-28 Lisbeth Illum Lipid vehicle drug delivery composition containing vitamin e
US6572884B1 (en) * 1999-07-28 2003-06-03 Daftary Gautam Vinod Parenteral Cisplatin emulsion
US20040137049A1 (en) * 2001-03-01 2004-07-15 Pai Srikanth Annappa Amphotericin b aqueous composition
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20070026058A1 (en) * 2004-05-11 2007-02-01 Lena Pereswetoff-Morath Method and composition for treating rhinitis
CN101804043A (zh) * 2010-04-30 2010-08-18 西安力邦制药有限公司 二联苯酚及其衍生物在治疗癫痫药物中的应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Barros et al. (2007). "Effects of the vitamin E in catalase activities in hippocampus after status epilepticus induced by pilocarpine in Wistar rats." Neuroscience Letters, 416: 227-230. *
Ogata et al. (2005). "Mechanism of Action of Dipropofol and Synergistic Action with Other Antibacterial Agents in Vitro." Biol. Pharm. Bull, 28(9): 1773-1775. *
Ogata et al. (2007). "Solubilization of Dipropofol, an Antibacterial Agent, Using Saccharide and Ascorbic Acid." Biol. Pharm. Bull, 30(8): 1565-1568. *
Ogata et al. (2007). "Solubilization of Dipropofol, and Antibacterial Agent, Using Saccharide and Ascorbic Acid." Biol. Pharm. Bull, 30(8): 1565-1568. *
Ogunmekan et al. (1989). "A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of D-a-Tocopheryl Acetate (Vitamin E), as Add-On Therapy, for Epilepsy in Children." Epilepsia, 30(1): 84-89. *
Ogunmekan et al. (1989). "A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of D-a-Tocopheryl Acetate (Vitamin E), as Add-On Therapy, for Epilepsy in Children." Epilepsia, 30(1):84-89. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154967B2 (en) 2012-02-06 2018-12-18 Xi'an Libang Pharmaceutical Co., Ltd 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and preparation methods therefor
US20180185299A1 (en) * 2015-01-13 2018-07-05 Xi'an Libang Pharmaceutical Co., Ltd The use of diphenol in preparation of medicines for prevention and treatment of cerebral ischemia
US10329243B2 (en) * 2015-01-13 2019-06-25 Xi'an Libang Pharmaceutical Co., Ltd Biphenyl derivative and uses thereof

Also Published As

Publication number Publication date
JP5748926B2 (ja) 2015-07-15
US10154967B2 (en) 2018-12-18
CN102525921B (zh) 2013-08-07
CA2865777C (fr) 2015-09-22
JP2015506378A (ja) 2015-03-02
WO2013117022A1 (fr) 2013-08-15
CN102525921A (zh) 2012-07-04
US20160235684A1 (en) 2016-08-18
EP2813215B1 (fr) 2016-07-13
CA2865777A1 (fr) 2013-08-15
EP2813215A4 (fr) 2015-07-08
EP2813215A1 (fr) 2014-12-17

Similar Documents

Publication Publication Date Title
US20220280446A1 (en) Stable cannabinoid formulations
US10154967B2 (en) 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and preparation methods therefor
KR102465046B1 (ko) 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
JP2003535884A (ja) プロポフォールの改善された注射可能な分散物
CN107970208B (zh) 一种丁苯酞注射液及其制备方法
JP2002502811A (ja) 亜硫酸塩を含有するプロポフォール組成物
AU2016371598A1 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
JP2018503637A (ja) ビフェニル誘導体及びその使用
EP3329940A1 (fr) Composition ophtalmique non irritante contenant de la cyclosporine, et procédé de préparation approprié
WO2020048533A1 (fr) Composition d'injection de nimodipine et son procédé de préparation
CN115804771A (zh) 一种具有长效缓释作用的脂质释药系统及其制备方法
CN100502850C (zh) 辣椒总碱类化合物与β-环糊精或β-环糊精衍生物的药用组合物
CN107405503A (zh) 鞣花酸二水合物在药物制剂中调节血糖水平的用途
US20140329774A1 (en) Injectable composition containing phosphatidylcholine devoid of sodium deoxycholate and preparing method thereof
US9161981B2 (en) Non-aqueous oily injectable formulation exhibiting preservative efficacy
EP4176869A1 (fr) Préparation et utilisation de nano-formulation de cannabis
US20160228387A1 (en) Solubilized formulation of coq10 for use in treatment of parkinson's disease
KR20170099911A (ko) 파라세타몰 주사 제제
CN116209427A (zh) 递送亲脂性活性成分的制剂
BR102016005548B1 (pt) Formulação micelar termorreversível contendo quercetina e vildagliptina para administração oral em diabetes tipo 1

Legal Events

Date Code Title Description
AS Assignment

Owner name: XI'AN LIBANG PHARMACEUTICAL CO., LTD, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, RUTAO;CHEN, TAO;GUO, SHUPAN;AND OTHERS;REEL/FRAME:033550/0280

Effective date: 20140815

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION